Olema Pharmaceuticals (OLMA) Competitors

Olema Pharmaceuticals (NASDAQ:OLMA) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Does the media favor OLMA or NAGE?

In the previous week, Niagen Bioscience had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Niagen Bioscience and 1 mentions for Olema Pharmaceuticals. Niagen Bioscience's average media sentiment score of 0.34 beat Olema Pharmaceuticals' score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Niagen Bioscience	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger earnings and valuation, OLMA or NAGE?

Niagen Bioscience has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$129.47M	-$2.01	-2.19
Niagen Bioscience	$99.60M	10.05	$8.55M	$0.17	74.76

Do analysts prefer OLMA or NAGE?

Olema Pharmaceuticals currently has a consensus price target of $24.50, indicating a potential upside of 456.82%. Niagen Bioscience has a consensus price target of $19.50, indicating a potential upside of 53.42%. Given Olema Pharmaceuticals' higher probable upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Niagen Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Niagen Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, OLMA or NAGE?

Olema Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500.

Do insiders & institutionals hold more shares of OLMA or NAGE?

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 16.4% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is OLMA or NAGE more profitable?

Niagen Bioscience has a net margin of 13.07% compared to Olema Pharmaceuticals' net margin of 0.00%. Niagen Bioscience's return on equity of 19.06% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-42.31%	-38.32%
Niagen Bioscience	13.07%	19.06%	12.20%

Summary

Niagen Bioscience beats Olema Pharmaceuticals on 9 of the 13 factors compared between the two stocks.